ECSP20033467A - Compuestos macrocíclicos para tratar enfermedades - Google Patents

Compuestos macrocíclicos para tratar enfermedades

Info

Publication number
ECSP20033467A
ECSP20033467A ECSENADI202033467A ECDI202033467A ECSP20033467A EC SP20033467 A ECSP20033467 A EC SP20033467A EC SENADI202033467 A ECSENADI202033467 A EC SENADI202033467A EC DI202033467 A ECDI202033467 A EC DI202033467A EC SP20033467 A ECSP20033467 A EC SP20033467A
Authority
EC
Ecuador
Prior art keywords
treat diseases
macrocyclic compounds
cancer
methods
present disclosure
Prior art date
Application number
ECSENADI202033467A
Other languages
English (en)
Inventor
Han Zhang
Jingrong Jean Cui
Jeffrey Whitten
Jane Ung
Evan W Rogers
Dayong Zhai
Wei Deng
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of ECSP20033467A publication Critical patent/ECSP20033467A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere a ciertos derivados macrocíclicos, las composiciones farmacéuticas que los contienen y los métodos para usarlos para tratar enfermedades, como el cáncer.
ECSENADI202033467A 2017-12-19 2020-06-19 Compuestos macrocíclicos para tratar enfermedades ECSP20033467A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607528P 2017-12-19 2017-12-19
US201862727124P 2018-09-05 2018-09-05
US201862779283P 2018-12-13 2018-12-13

Publications (1)

Publication Number Publication Date
ECSP20033467A true ECSP20033467A (es) 2020-09-30

Family

ID=66992951

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202033467A ECSP20033467A (es) 2017-12-19 2020-06-19 Compuestos macrocíclicos para tratar enfermedades

Country Status (29)

Country Link
US (3) US10745416B2 (es)
EP (2) EP3728271B1 (es)
JP (2) JP7194188B2 (es)
KR (1) KR102814342B1 (es)
CN (1) CN111511746B (es)
AU (1) AU2018392332B2 (es)
BR (1) BR112020012319A2 (es)
CA (1) CA3083674A1 (es)
CL (1) CL2020001632A1 (es)
CY (1) CY1125772T1 (es)
DK (1) DK3728271T3 (es)
EC (1) ECSP20033467A (es)
ES (1) ES2929467T3 (es)
HR (1) HRP20221502T1 (es)
HU (1) HUE060711T2 (es)
IL (1) IL275265B2 (es)
JO (1) JOP20200152A1 (es)
LT (1) LT3728271T (es)
MX (1) MX2020006490A (es)
PE (1) PE20200937A1 (es)
PH (1) PH12020550901A1 (es)
PL (1) PL3728271T3 (es)
PT (1) PT3728271T (es)
RS (1) RS63787B1 (es)
SG (1) SG11202005590PA (es)
SI (1) SI3728271T1 (es)
SM (1) SMT202200443T1 (es)
TW (1) TW201930312A (es)
WO (1) WO2019126121A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
KR102717072B1 (ko) 2017-10-18 2024-10-15 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
RS63787B1 (sr) 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti
PE20210655A1 (es) 2017-12-19 2021-03-31 Bristol Myers Squibb Co Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
EP3833372A4 (en) 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
WO2020257189A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for treating disease
WO2020257165A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
WO2020257169A1 (en) 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
WO2021027503A1 (zh) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 三环类化合物、其制备方法、中间体及应用
TW202134249A (zh) * 2019-12-03 2021-09-16 美商特普醫葯公司 用於治療疾病的巨環
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
WO2021244609A1 (zh) 2020-06-04 2021-12-09 成都倍特药业股份有限公司 具有大环结构的化合物及其用途
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
IL301385A (en) 2020-09-16 2023-05-01 Alumis Inc TYK2 inhibitors and their use
CN116635076A (zh) * 2020-12-17 2023-08-22 荣山医药股份有限公司 大环化合物及其用途
WO2023060022A1 (en) * 2021-10-05 2023-04-13 Turning Point Therapeutics, Inc. Synthesis of macrocyclic compounds
CN119630675A (zh) * 2022-07-22 2025-03-14 南京明德新药研发有限公司 含三并环的大环类化合物及其应用
JP2025528836A (ja) * 2022-08-17 2025-09-02 ツリーライン バイオサイエンシズ インコーポレイテッド ピリドピリミジンＫＲａｓ阻害剤
JP7571173B2 (ja) 2023-02-24 2024-10-22 キヤノン株式会社 撮像装置、撮像装置の制御方法、及びプログラム

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2149869T3 (es) * 1993-03-25 2000-11-16 Upjohn Co Derivados de indol sustituidos por formil o ciano con actividad dopominergica.
KR100340159B1 (ko) 1993-12-07 2002-11-23 일라이 릴리 앤드 캄파니 단백질키나제c억제제
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
RU2275373C2 (ru) 2000-12-08 2006-04-27 Орто-Макнейл Фармасьютикал, Инк. Макрогетероциклические соединения
ES2668834T3 (es) 2008-09-08 2018-05-22 Merck Serono Sa Pirimidinas macrociclicas como inhibidores de proteína quinasas
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
BRPI0914404A2 (pt) 2008-10-31 2019-03-06 Genentech Inc "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente"
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
KR20140009259A (ko) * 2010-11-19 2014-01-22 에프. 호프만-라 로슈 아게 피라졸로피리딘 및 tyk2 억제제로서 이의 용도
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
MX2014001945A (es) 2011-08-19 2014-03-27 Merck Sharp & Dohme Procedimiento e intermedios para la preparacion de macrolactamas.
MX347765B (es) 2011-09-30 2017-05-12 Oncodesign Sa Inhibidores macrociclicos de la quinasa flt3.
CA2863892C (en) 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
RU2014140739A (ru) 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
DK2834243T3 (en) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
WO2015112806A2 (en) 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
WO2016014551A1 (en) * 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
RU2732405C2 (ru) 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
BR112018000297A2 (pt) 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
WO2017015367A1 (en) 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
ES2812336T3 (es) * 2016-03-03 2021-03-16 Shenzhen Targetrx Inc Macrocíclico y composición que comprende el mismo
CN106008531B (zh) * 2016-05-30 2019-01-11 上海交通大学 多环稠合大环内酰胺类化合物的抗胰腺癌用途
AU2017302019A1 (en) 2016-07-28 2019-02-07 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
PT3658148T (pt) 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
KR102717072B1 (ko) 2017-10-18 2024-10-15 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
RS63787B1 (sr) 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti
US20210087206A1 (en) * 2017-12-19 2021-03-25 Turning Point Therapeutics, Inc. Macrocyclic kinase inhibitors and their use
PE20210655A1 (es) 2017-12-19 2021-03-31 Bristol Myers Squibb Co Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa
GB201721235D0 (en) 2017-12-19 2018-01-31 Syngenta Participations Ag Polymorphs
WO2019120267A1 (zh) 2017-12-22 2019-06-27 成都先导药物开发股份有限公司 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
US11584759B2 (en) 2018-04-18 2023-02-21 Hitgen Inc. Macrocyclic kinase inhibitor

Also Published As

Publication number Publication date
PL3728271T3 (pl) 2023-01-23
MX2020006490A (es) 2020-08-17
US20200190110A1 (en) 2020-06-18
WO2019126121A1 (en) 2019-06-27
EP3728271A1 (en) 2020-10-28
IL275265B2 (en) 2023-07-01
JOP20200152A1 (ar) 2022-10-30
PH12020550901A1 (en) 2021-05-17
AU2018392332A1 (en) 2020-06-11
CN111511746A (zh) 2020-08-07
RS63787B1 (sr) 2022-12-30
IL275265A (en) 2020-07-30
AU2018392332B2 (en) 2023-08-03
SI3728271T1 (sl) 2023-01-31
JP7194188B2 (ja) 2022-12-21
BR112020012319A2 (pt) 2020-11-24
JP2021506850A (ja) 2021-02-22
IL275265B1 (en) 2023-03-01
US20200392160A1 (en) 2020-12-17
HRP20221502T1 (hr) 2023-03-31
JP2023027237A (ja) 2023-03-01
LT3728271T (lt) 2022-12-12
CA3083674A1 (en) 2019-06-27
PE20200937A1 (es) 2020-09-17
US10745416B2 (en) 2020-08-18
US20220306652A1 (en) 2022-09-29
CY1125772T1 (el) 2026-02-25
ES2929467T3 (es) 2022-11-29
KR20200101358A (ko) 2020-08-27
SG11202005590PA (en) 2020-07-29
CL2020001632A1 (es) 2020-11-20
EP4151641A1 (en) 2023-03-22
TW201930312A (zh) 2019-08-01
HUE060711T2 (hu) 2023-04-28
PT3728271T (pt) 2022-10-06
EP3728271B1 (en) 2022-09-28
SMT202200443T1 (it) 2023-01-13
EP3728271A4 (en) 2021-06-23
CN111511746B (zh) 2024-01-09
DK3728271T3 (da) 2022-12-19
KR102814342B1 (ko) 2025-05-29
US11286265B2 (en) 2022-03-29

Similar Documents

Publication Publication Date Title
CL2020001632A1 (es) Compuestos macrocíclicos para tratar enfermedades.
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
MX2023001876A (es) Derivados de rapamicina.
CO2020000633A2 (es) Compuestos macrocíclicos y usos de los mismos
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2017011484A2 (es) Inhibidores de bromodominio
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
BR112016023558A2 (pt) compostos úteis como imunomoduladores
CL2017003067A1 (es) Piridinas sustituidas y método de uso
MX2021006734A (es) Metodo para tratar el cancer.
UY33883A (es) Novedosos derivados heterocíclicos
CR20150610A (es) Compuestos de pirimidino sustituido y derivados para combatir plagas de animales
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CR20170157A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial
MX2018013701A (es) Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
ECSP18056196A (es) Derivados de indano
CR20150641U (es) Composiciones farmacéuticas